New Investments, Scientific Contributions, Proposed Acquisition Updates, Donations, and Stock Price Movements - Research Report on UnitedHealth Group, AstraZeneca, Salix, Health Net, and Volcano
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 17, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting UnitedHealth Group, Inc. (NYSE: UNH), AstraZeneca PLC (NYSE: AZN), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Health Net, Inc. (NYSE: HNT) and Volcano Corporation (NASDAQ: VOLC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
UnitedHealth Group, Inc. Research Report
On December 10, 2013, UnitedHealth Group, Inc. (UnitedHealth Group) reported that along with the Minnesota Equity Fund (MEF), the Company is investing $9.8 million in equity to aid the development and construction of the Duluth Hillside Apartments, a new 44-unit affordable-housing community in the heart of downtown. Commenting on the investment, Duluth Mayor Don Ness said, "We are grateful to UnitedHealth Group and MEF for providing the critical equity needed to get construction underway for the Hillside Apartments, which is an important part of Duluth's revitalization and redevelopment." John Miklausich, Site Director for UnitedHealthcare's offices in Duluth, added, "UnitedHealth Group is working with MEF to provide the critical funding for Hillside Apartments that will bring new affordable-housing opportunities to Duluth. This development project is an example of many partners coming together to help enhance our city and provide greater access to affordable housing." The Full Research Report on UnitedHealth Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/73e5_UNH
AstraZeneca PLC Research Report
On December 9, 2013, AstraZeneca PLC (AstraZeneca) reported that it plans to donate its Environmental Laboratory in Brixham to Plymouth University. According to the Company, the donation of the facility and its equipment will help ensure that the laboratory continues to serve scientific and research purposes, benefitting the Torbay region and beyond. Steve Rumford, Head of the Environment Team at AstraZeneca commented, "We made the decision in October to close our Brixham site as operating an environmental research laboratory is not a core part of AstraZeneca's strategy. However our aim has been to ensure the laboratory and its state of the art facilities remain in use for scientific purposes. Plymouth University is a world-class teaching and research institution and we are confident that we have chosen the right partner to secure a successful future for the site." Professor Wendy Purcell, Plymouth University Vice-Chancellor added, "We are determined to leverage our academic credentials and enterprise mission to further develop the site into an international centre of excellence for marine and environmental research." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/09cc_AZN
Salix Pharmaceuticals Ltd. Research Report
On December 10, 2013, Salix Pharmaceuticals Ltd. (Salix) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act) regarding Salix's proposed acquisition of Santarus, Inc. (Santarus) has expired. The Company informed that the expiration of the HSR Act waiting period satisfies one of the conditions to the completion of the tender offer. The completion of the tender offer remains subject to other customary conditions as set forth in the Offer to Purchase filed by Purchaser, Salix and Intermediary with the U.S. SEC on December 3, 2013, including the tender of at least a majority of the outstanding shares of common stock of Santarus on a fully diluted basis. Salix said that the tender offer is slated to close at 12:00 Midnight, New York City time, on December 31, 2013 (unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC). The Full Research Report on Salix Pharmaceuticals Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/04fa_SLXP
Health Net, Inc. Research Report
On December 11, 2013, Health Net, Inc. (Health Net) reported that the Health Net Foundation, Inc., the charitable foundation of the Company, has pledged to donate $50,000 to the American Red Cross Los Angeles Region to contribute to its efforts on behalf of the victims of Typhoon Haiyan in the Philippines. In addition, the Company informed that Health Net associates raised $16,000, which increased the overall donation amount to $66,000. Paul Schulz, CEO of the American Red Cross Los Angeles Region, commented, "Thanks to the generosity of Health Net Foundation and Health Net associates, the Red Cross will be better able to provide critical support to Typhoon Haiyan survivors. Contributions to our humanitarian efforts will help survivors recover and rebuild." Patricia Clarey, President of Health Net Foundation, added, "Our thoughts are with the families suffering in the aftermath of Haiyan, and we want to help them however we can. We support the American Red Cross and its efforts to provide critical resources and disaster relief to those in need." The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/6995_HNT
Volcano Corporation Research Report
On December 12, 2013, Volcano Corporation's (Volcano) stock declined 2.29%, ending the day at $21.36. Over the previous three trading sessions, shares of Volcano declined 7.09% compared to the Nasdaq Composite which also declined 1.73% during the same period. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/14bf_VOLC
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsCorner.comSOURCE Analysts' Corner
Share this article